| Nome |
# |
|
Entinostat for the treatment of breast cancer, file dfa8b99f-34e8-748b-e053-3a05fe0a3a96
|
831
|
|
Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology, file dfa8b9a7-3b58-748b-e053-3a05fe0a3a96
|
769
|
|
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines, file dfa8b99b-c6c1-748b-e053-3a05fe0a3a96
|
598
|
|
Managing side effects of immune checkpoint inhibitors in breast cancer, file dfa8b9a7-30c4-748b-e053-3a05fe0a3a96
|
442
|
|
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies, file dfa8b9a6-3470-748b-e053-3a05fe0a3a96
|
388
|
|
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer, file dfa8b99d-1c42-748b-e053-3a05fe0a3a96
|
301
|
|
Global cancer control: responding to the growing burden, rising costs and inequalities in access, file dfa8b99a-94db-748b-e053-3a05fe0a3a96
|
295
|
|
RNAi screens identify CHD4 as an essential gene in breast cancer growth, file dfa8b996-deda-748b-e053-3a05fe0a3a96
|
279
|
|
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review, file dfa8b9a7-0a7a-748b-e053-3a05fe0a3a96
|
252
|
|
Expression of tumor-associated antigens in breast cancer subtypes, file dfa8b9a0-784e-748b-e053-3a05fe0a3a96
|
227
|
|
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets, file dfa8b99a-c2e6-748b-e053-3a05fe0a3a96
|
196
|
|
Pten alterations and their role in cancer management: Are we making headway on precision medicine?, file dfa8b9a2-b15e-748b-e053-3a05fe0a3a96
|
172
|
|
Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer, file dfa8b99b-fff7-748b-e053-3a05fe0a3a96
|
143
|
|
WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells, file dfa8b9a2-ebc7-748b-e053-3a05fe0a3a96
|
142
|
|
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients : a Single-Institute Study, file dfa8b99a-a57b-748b-e053-3a05fe0a3a96
|
128
|
|
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, file dfa8b9a7-3f2e-748b-e053-3a05fe0a3a96
|
128
|
|
Impact of autoimmune diseases on outcome of patients with early breast cancer, file dfa8b99a-707b-748b-e053-3a05fe0a3a96
|
118
|
|
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials, file dfa8b9a5-dfe5-748b-e053-3a05fe0a3a96
|
117
|
|
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00, file dfa8b9a6-d5de-748b-e053-3a05fe0a3a96
|
114
|
|
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date., file dfa8b99a-822e-748b-e053-3a05fe0a3a96
|
113
|
|
Immune checkpoint blockade in cancer treatment : a double-edged sword cross-targeting the host as an "innocent bystander", file dfa8b99a-d059-748b-e053-3a05fe0a3a96
|
113
|
|
Biopsy confirmation of metastatic sites in breast cancer patients : clinical impact and future perspectives, file dfa8b99b-1508-748b-e053-3a05fe0a3a96
|
110
|
|
Immune approaches to the treatment of breast cancer, around the corner?, file dfa8b99b-1511-748b-e053-3a05fe0a3a96
|
106
|
|
HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence, file dfa8b99f-01e5-748b-e053-3a05fe0a3a96
|
106
|
|
Antibody–drug conjugates in solid tumors: a look into novel targets, file dfa8b9a6-4a77-748b-e053-3a05fe0a3a96
|
102
|
|
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs, file dfa8b99f-7c4c-748b-e053-3a05fe0a3a96
|
100
|
|
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study, file dfa8b9a5-1f3a-748b-e053-3a05fe0a3a96
|
89
|
|
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management, file dfa8b9a7-b359-748b-e053-3a05fe0a3a96
|
80
|
|
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials, file dfa8b9a2-a6d8-748b-e053-3a05fe0a3a96
|
79
|
|
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer, file dfa8b9a5-d6a9-748b-e053-3a05fe0a3a96
|
68
|
|
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer, file dfa8b9aa-53ce-748b-e053-3a05fe0a3a96
|
67
|
|
Tumour dormancy and clinical implications in breast cancer, file dfa8b99b-2238-748b-e053-3a05fe0a3a96
|
55
|
|
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials, file dfa8b9aa-2ac0-748b-e053-3a05fe0a3a96
|
51
|
|
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution, file 7bdf0812-c6a5-45e4-b81c-9bd6063e8ad1
|
50
|
|
Highlights from the 13th St Gallen International Breast Cancer Conference 2013 : access to innovation for patients with breast cancer: How to speed it up?, file dfa8b99b-6724-748b-e053-3a05fe0a3a96
|
46
|
|
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents, file 3313c5a7-8117-463e-ac51-1492ce112453
|
38
|
|
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials, file dfa8b9a9-e0ee-748b-e053-3a05fe0a3a96
|
29
|
|
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management, file e322fc45-a51b-4eb9-a937-7d1012b995a2
|
17
|
|
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors, file 1a546335-d67d-46c8-8910-27494840e7a8
|
16
|
|
Future potential targets of antibody-drug conjugates in breast cancer, file 33c86eb6-b4cf-4c69-8dfa-a0c492e6fccb
|
16
|
|
Cancer immunotherapy: tools and strategies to unmask a master of disguise, file 4df593fb-a12d-4f96-857e-da20908022ab
|
16
|
|
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population, file f765c9d1-af48-4438-8db5-0c2ef63f6e0d
|
12
|
|
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study, file 16e0ace9-6686-48af-b579-4a4c0df913c1
|
11
|
|
A set of easy and stringent criteria to identify immune-related adverse events (IrAE Scoring System, ISS) improves correlation with outcome in a phase 1-2 trial population, file 488bbd81-9e06-49ce-943b-eb05eb696b11
|
11
|
|
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors : a Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group : Part 1 : Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research, file dfa8b999-480e-748b-e053-3a05fe0a3a96
|
8
|
|
Cardiotoxicity of anticancer treatments : epidemiology, detection, and management, file dfa8b99b-1337-748b-e053-3a05fe0a3a96
|
8
|
|
Liquid biopsies for solid tumors : understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies, file dfa8b99a-cddb-748b-e053-3a05fe0a3a96
|
7
|
|
Molecular pathways : human leukocyte antigen G(HLA-G), file dfa8b99a-dddc-748b-e053-3a05fe0a3a96
|
7
|
|
Strategies to modulate the immune system in breast cancer : checkpoint inhibitors and beyond, file dfa8b99b-0fab-748b-e053-3a05fe0a3a96
|
7
|
|
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer, file dfa8b99b-7766-748b-e053-3a05fe0a3a96
|
7
|
|
Best management of locally advanced inoperable breast cancer, file dfa8b99b-215a-748b-e053-3a05fe0a3a96
|
6
|
|
Mechanism of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist, file dfa8b994-eef9-748b-e053-3a05fe0a3a96
|
5
|
|
Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer, file dfa8b99a-de08-748b-e053-3a05fe0a3a96
|
5
|
|
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer, file dfa8b99b-1740-748b-e053-3a05fe0a3a96
|
5
|
|
No link between breast cancer and meningioma : results from a large monoinstitutional retrospective analysis, file dfa8b99b-1b16-748b-e053-3a05fe0a3a96
|
5
|
|
Developing an effective breast cancer vaccine : challenges to achieving sterile immunity versus resetting equilibrium, file dfa8b99b-2543-748b-e053-3a05fe0a3a96
|
5
|
|
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy, file dfa8b9a0-a937-748b-e053-3a05fe0a3a96
|
5
|
|
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials, file dfa8b9a8-17a4-748b-e053-3a05fe0a3a96
|
5
|
|
Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer, file fa17240e-3b2b-4852-81ab-ddc5c859d602
|
5
|
|
Crosstalk between bone niche and immune system : osteoimmunology signaling as a potential target for cancer treatment, file dfa8b99a-7f5e-748b-e053-3a05fe0a3a96
|
4
|
|
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation : a comprehensive review, file dfa8b99a-926b-748b-e053-3a05fe0a3a96
|
4
|
|
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : results from Neo-ALTTO, file dfa8b99a-9dd9-748b-e053-3a05fe0a3a96
|
4
|
|
Neoadjuvant model for testing emerging targeted therapies in breast cancer, file dfa8b99a-a606-748b-e053-3a05fe0a3a96
|
4
|
|
Monitoring tumor-derived cell-free DNA in patients with solid tumors : clinical perspectives and research opportunities, file dfa8b99b-2527-748b-e053-3a05fe0a3a96
|
4
|
|
Tumor-infiltrating lymphocytes (TILs) in paired samples from patients with phenotypic switch from early luminal-like to metastatic triple-negative breast cancer, file cc94710a-5f6c-41a2-a391-41255a410895
|
3
|
|
Locoregional recurrence in patients with HER2 positive breast cancer, file dfa8b990-c251-748b-e053-3a05fe0a3a96
|
3
|
|
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer, file dfa8b990-f444-748b-e053-3a05fe0a3a96
|
3
|
|
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer : a systematic review of randomized controlled trials, file dfa8b99a-5678-748b-e053-3a05fe0a3a96
|
3
|
|
The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations, file dfa8b99a-c3dd-748b-e053-3a05fe0a3a96
|
3
|
|
Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer, file dfa8b99b-1d68-748b-e053-3a05fe0a3a96
|
3
|
|
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial, file dfa8b99d-1cb1-748b-e053-3a05fe0a3a96
|
3
|
|
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer, file dfa8b9a3-0274-748b-e053-3a05fe0a3a96
|
3
|
|
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus, file dfa8b9a5-e433-748b-e053-3a05fe0a3a96
|
3
|
|
Adjuvant treatment of early male breast cancer, file dfa8b9a6-70cc-748b-e053-3a05fe0a3a96
|
3
|
|
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents, file 7274a766-ca39-47ea-b580-0b41c0acc128
|
2
|
|
Immune-related adverse events are correlated with significantly improved outcome in a phase I trial population exposed to combination immunotherapy, file 82391f77-cfe8-4eeb-ac5c-656d75dc4f52
|
2
|
|
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?, file 93bc2014-8bd6-4d8b-8b8c-1d83a553ba84
|
2
|
|
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00, file dfa8b995-4307-748b-e053-3a05fe0a3a96
|
2
|
|
Breast conservation following neoadjuvant therapy for breast cancer in the modern era : are we losing the opportunity?, file dfa8b99a-d857-748b-e053-3a05fe0a3a96
|
2
|
|
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer, file dfa8b9a5-b46b-748b-e053-3a05fe0a3a96
|
2
|
|
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis, file dfa8b9a6-2d2d-748b-e053-3a05fe0a3a96
|
2
|
|
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis, file dfa8b9a6-8924-748b-e053-3a05fe0a3a96
|
2
|
|
HER2-Low Breast Cancer: a New Subtype?, file 2945c94b-1fa5-471e-aa48-0e3c2292cae8
|
1
|
|
Metaplastic breast cancer: an all-round multidisciplinary consensus, file 2ba1d62d-e7b3-4340-9da2-7c7ea96303b5
|
1
|
|
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials, file 7c641018-1285-4614-b3dd-c43dfe2acb2e
|
1
|
|
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?, file ae820237-2427-4c7d-a823-2118c511c09f
|
1
|
|
Breast Cancer Genetics: Diagnostics and Treatment, file b6791e12-8f0d-4bb4-ab81-b6d9aec546fb
|
1
|
|
Characterization of low HER2 expressions in de-novo metastatic breast cancer, file bf38567a-0f9f-4a8e-8e20-0fa2d2e229ca
|
1
|
|
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: a randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine, file dfa8b992-3a36-748b-e053-3a05fe0a3a96
|
1
|
|
Over-using chemotherapy in the adjuvant setting, file dfa8b996-cfb6-748b-e053-3a05fe0a3a96
|
1
|
|
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?, file dfa8b99a-be4e-748b-e053-3a05fe0a3a96
|
1
|
|
Erratum: Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study [Ann Oncol, 25, (2015) 611-618] DOI: 10.1093/annonc/mdt556, file dfa8b99b-e9a1-748b-e053-3a05fe0a3a96
|
1
|
|
Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis, file dfa8b99d-1c9f-748b-e053-3a05fe0a3a96
|
1
|
|
Peptide vaccines in early breast cancer, file dfa8b99d-ba30-748b-e053-3a05fe0a3a96
|
1
|
|
Targeting the subtypes of breast cancer: Rethinking investigational drugs, file dfa8b99e-ae12-748b-e053-3a05fe0a3a96
|
1
|
|
Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?, file dfa8b99f-7011-748b-e053-3a05fe0a3a96
|
1
|
|
Pharmacological management of male breast cancer, file dfa8b9a3-1f9d-748b-e053-3a05fe0a3a96
|
1
|
|
Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours, file dfa8b9a5-c8c2-748b-e053-3a05fe0a3a96
|
1
|
|
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents, file dfa8b9a6-61be-748b-e053-3a05fe0a3a96
|
1
|
|
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials, file dfa8b9a6-68b5-748b-e053-3a05fe0a3a96
|
1
|
| Totale |
7.315 |